Schultz RM - Search Results

1

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM. Shih C, et al. Among authors: schultz rm. Cancer Res. 1997 Mar 15;57(6):1116-23. Cancer Res. 1997. PMID: 9067281

2

A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.

Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB, Mendelsohn LG. Habeck LL, et al. Among authors: schultz rm. Cancer Res. 1994 Feb 15;54(4):1021-6. Cancer Res. 1994. PMID: 8313357

3

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.

Mendelsohn LG, Shih C, Schultz RM, Worzalla JF. Mendelsohn LG, et al. Among authors: schultz rm. Invest New Drugs. 1996;14(3):287-94. doi: 10.1007/BF00194532. Invest New Drugs. 1996. PMID: 8958184

4

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.

Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, Mendelsohn LG. Tonkinson JL, et al. Among authors: schultz rm. Cancer Chemother Pharmacol. 1997;39(6):521-31. doi: 10.1007/s002800050608. Cancer Chemother Pharmacol. 1997. PMID: 9118464

5

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C, Mendelsohn LG, Seitz DE, Tonkinson JL. Chen VJ, et al. Among authors: schultz rm. Br J Cancer. 1998;78 Suppl 3(Suppl 3):27-34. doi: 10.1038/bjc.1998.751. Br J Cancer. 1998. PMID: 9717988 Free PMC article.

6

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Shih C, et al. Among authors: schultz rm. Adv Enzyme Regul. 1998;38:135-52. doi: 10.1016/s0065-2571(97)00017-4. Adv Enzyme Regul. 1998. PMID: 9762351

7

Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.

Worzalla JF, Shih C, Schultz RM. Worzalla JF, et al. Among authors: schultz rm. Anticancer Res. 1998 Sep-Oct;18(5A):3235-9. Anticancer Res. 1998. PMID: 9858888

8

The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents.

Gossett LS, Habeck LL, Shackelford KA, Mendelsohn LG, Gates SB, Worzalla JF, Self TD, Theobald KS, Andis SL, Schultz RM, Shih C. Gossett LS, et al. Among authors: schultz rm. Bioorg Med Chem Lett. 1999 Jan 4;9(1):75-8. doi: 10.1016/s0960-894x(98)00683-0. Bioorg Med Chem Lett. 1999. PMID: 9990460

9

Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.

Schultz RM, Patel VF, Worzalla JF, Shih C. Schultz RM, et al. Anticancer Res. 1999 Jan-Feb;19(1A):437-43. Anticancer Res. 1999. PMID: 10226579

10

Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C, Mendelsohn LG, Seitz DE, Tonkinson JL. Chen VJ, et al. Among authors: schultz rm. Semin Oncol. 1999 Apr;26(2 Suppl 6):48-54. Semin Oncol. 1999. PMID: 10598555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

461 results

Search Page